- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01497717
Efficacy of Humira in Behcet Patients With Arthritis
Hypothesis - Behcet's disease is a multisystemic chronic relapsing inflammatory disease, classified among the vasculitides. The clinical manifestations include mucocutaneous lesions, articular, ocular, vascular, gastrointestinal and/or central nervous system involvement.
The aetiology of Behcet's disease is unknown, however. Experimental evidence suggests that TNF-α may play an important role in the pathogenesis of the disease.
To date, case reports and small open-short term studies report the efficacy of anti-TNFα therapy (Infliximab and Etanercept), especially regarding ocular and mucocutaneous involvement in Behcet.
There are no double blind long term studies on larger number of patients regarding the efficacy of anti-TNFα, especially Humira in healing arthritis +/- other manifestations of the disease.
Study Overview
Detailed Description
Study Design (including visit schedule, dosing and procedures/methods):
Screen visit, 1st visit -treatment initiation, follow-up visits - after 1 month and afterwards every 8 weeks for 24 weeks.
Screen visit: informed consent, medical history,inclusion and exclusion criteria, pregnancy test, vital signs, physical examination, joint evaluation (no. of tender joints, no. of swollen joints), patient/investigator global disease activity, pain VAS, HAQ, Behcet Disease Current Activity Forms (BDACF), ECG, PPD and chest X-ray screening for tuberculosis, routine labs (performed at local HMO as a routine follow-up of the patient treatment with DMARD's): CBC, blood chemistry, ESR, CRP, urinalysis, HbsAg and AntiHCV, immunology labs (rheumatoid factor, anti-CCP, anti nuclear antibody - ANA).
An induration of greater than 5 mm will be considered a positive PPD reaction.
Follow up visits .: Vital signs, joint evaluation, patient/investigator global disease activity, pain VAS, HAQ, BDACF, routine labs (performed at local HMO as a routine follow-up of the patient treatment with DMARD's): CBC, blood chemistry, ESR, CRP, urinalysis, research blood samples for storage.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel, 31096
- Rheumatology Unit, Rambam Health Care Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to give written informed consent and comply with the requirements of the study protocol.
- Patients with Behcet disease ,who fulfilled the International Study group criteria for Behcet Disease.
- Experienced an inadequate response to previous or current treatment with one or more DMARDs because of inadequate efficacy or side effects.
- DMARDS and/or corticosteroids (< or equivalent to 10mg/d prednisone) permitted if stable for at least 4 weeks prior to screening. NSAIDs permitted if stable for at least 2 weeks prior to screening.
- Active peripheral arthritis at screening (tenderness and swelling of at least 3 small joints or one large joint) OR axial involvement (active enthesitis or spondylitis)
- Age 18-80 years.
- If female and of childbearing potential, a negative urine pregnancy test within 2 weeks prior to therapy, and using reliable means of contraception.
Exclusion Criteria:
- Rheumatic autoimmune disease other than Behcet (Rheumatoid arthritis, SLE, scleroderma, etc).
- Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders.
- Known active bacterial, viral, fungal, mycobacterial or other infection, or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
- History of lymphoproliferative or hematologic malignancy. History of any other type of cancer in the past 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adalimumab, Behcet with arthritis
|
Open label pilot trial. The study includes 3 phases :
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in DAS28
Time Frame: Week 24
|
The proportion of patients with improvement in arthritis (DAS 28) at week 24 -changes from screening in DAS 28 , HAQ, , CRP.
ANOVA analysis and descriptive statistics.
An interim evaluation of the above parameters will be performed at week 16 (visit 4) and yearly afterwards for 3 more years in those patients who will continue drug study during the extension period
|
Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yolanda Braun, MD, Rheumatology Unit, Rambam Health Care Campus, B. Rappaport Faculty of Medicine, Technion - Institute of Technology, Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Eye Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Uveitis, Anterior
- Panuveitis
- Uveitis
- Uveal Diseases
- Vasculitis
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vascular
- Arthritis
- Behcet Syndrome
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Adalimumab
Other Study ID Numbers
- 0488-09RMB
- A06-197 (Other Identifier: Protocol Number of Collaborator - Abbott Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis; Behcet
-
AmgenRecruitingJuvenile Psoriatic Arthritis | Behçet's DiseaseSpain, Israel, Turkey, Greece
-
Novartis PharmaceuticalsCompleted
-
Janssen Korea, Ltd., KoreaCompleted
-
Yonsei UniversityRecruitingIntestinal Behcet DiseaseKorea, Republic of
-
Silk Road Therapies, Inc.Not yet recruitingBehcet Syndrome | Behcet DiseaseUnited States
-
Nobel PharmaceuticalsAinos, Inc. (f/k/a Amarillo Biosciences Inc.CompletedBehcet Syndrome | Behcet Disease | Mucocutaneous UlcerationTurkey
-
Novartis PharmaceuticalsCompletedBehcet DiseaseIndia, Turkey, Spain, Germany, Italy, France, Israel, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Switzerland, Taiwan, Tunisia
-
Assiut UniversityNot yet recruitingBehcet Disease and Vascular Involvement
-
Peking Union Medical College HospitalNot yet recruitingAneurysm | Behcet Syndrome, Vascular TypeChina
Clinical Trials on Adalimumab (Humira)
-
AbbottCompletedRheumatoid ArthritisSpain
-
AbbottTerminatedRheumatoid ArthritisPuerto Rico
-
Hvidovre University HospitalAbbottCompletedArthritis | Joint Diseases | Rheumatoid ArthritisDenmark
-
PfizerCompletedHealthyUnited States, Belgium
-
AbbottCompleted
-
SandozHexal AGCompletedRheumatoid ArthritisUnited States, United Kingdom, Hungary, Italy, Malaysia, Serbia, Mexico, Spain, Czechia, Poland, Germany, Romania, Russian Federation
-
Radboud University Medical CenterErasmus Medical CenterActive, not recruitingCrohn Disease | Crohn Disease in RemissionNetherlands
-
BiocadCompleted
-
Dr. FRANCISCO J. BLANCO-GARCIACompletedA 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic ArthritisPsoriatic ArthritisSpain